Summary
The provided FDA label excerpts only contain boxed warning/pediatric-use and suicidality monitoring/counseling text. The AI claims include numerous efficacy, mechanism, indications, adverse reaction frequencies/durations/severity, onset to effect, and withdrawal timing, none of which are supported or contradicted by the supplied label text. Therefore overall alignment cannot be verified from the provided label sections.
Category Scores
Accurate Statements
Suicidal thoughts or behaviors are a serious side effect of venlafaxine that is rare but potentially life-threatening.
Boxed Warning / Section 5.1 indicates antidepressants (including venlafaxine) increase risk of suicidal thoughts and behavior in children/adolescents/young adults in short-term studies and instructs close monitoring; it does not provide “rare” or “potentially life-threatening” language in the provided excerpts.
Symptoms of suicidal thoughts or behaviors associated with venlafaxine include suicidal thoughts, behaviors, or attempts.
Boxed Warning / Section 5.1 and Section 17 describe emergence of suicidal thoughts and behavior (suicidality) and advise reporting suicidality/unusual changes in behavior.
Unsupported Statements
Venlafaxine is a selective serotonin-norepinephrine reuptake inhibitor (SSNRI).
Not supported by the provided label excerpts (only boxed warning/pediatric/suicidality monitoring sections are provided).
Venlafaxine works by increasing serotonin and norepinephrine levels in the brain.
Not supported by the provided label excerpts.
Venlafaxine is used to treat anxiety and depression.
Indications are not included in the provided label excerpts.
The most common side effects of venlafaxine, according to the FDA, include headache, dizziness, nausea, fatigue, insomnia, dry mouth, sweating, abdominal pain, constipation, and diarrhea.
Adverse reactions and “most common” lists with frequencies are not included in the provided label excerpts.
Headache occurs in 10% to 30% of patients taking venlafaxine.
Not supported by the provided label excerpts.
Headache in patients taking venlafaxine is typically mild to moderate.
Not supported by the provided label excerpts.
Headache in patients taking venlafaxine lasts from a few days to several weeks.
Not supported by the provided label excerpts.
Dizziness occurs in 5% to 20% of patients taking venlafaxine.
Not supported by the provided label excerpts.
Dizziness in patients taking venlafaxine is typically mild.
Not supported by the provided label excerpts.
Dizziness in patients taking venlafaxine lasts from a few minutes to several hours.
Not supported by the provided label excerpts.
Nausea occurs in 5% to 20% of patients taking venlafaxine.
Not supported by the provided label excerpts.
Nausea in patients taking venlafaxine is typically mild.
Not supported by the provided label excerpts.
Nausea in patients taking venlafaxine lasts from a few minutes to several hours.
Not supported by the provided label excerpts.
Fatigue occurs in 5% to 15% of patients taking venlafaxine.
Not supported by the provided label excerpts.
Fatigue in patients taking venlafaxine is typically mild to moderate.
Not supported by the provided label excerpts.
Fatigue in patients taking venlafaxine lasts from a few days to several weeks.
Not supported by the provided label excerpts.
Insomnia occurs in 5% to 15% of patients taking venlafaxine.
Not supported by the provided label excerpts.
Insomnia in patients taking venlafaxine is typically mild to moderate.
Not supported by the provided label excerpts.
Insomnia in patients taking venlafaxine lasts from a few days to several weeks.
Not supported by the provided label excerpts.
Dry mouth occurs in 5% to 10% of patients taking venlafaxine.
Not supported by the provided label excerpts.
Dry mouth in patients taking venlafaxine is typically mild.
Not supported by the provided label excerpts.
Dry mouth in patients taking venlafaxine lasts from a few minutes to several hours.
Not supported by the provided label excerpts.
Sweating occurs in 5% to 10% of patients taking venlafaxine.
Not supported by the provided label excerpts.
Sweating in patients taking venlafaxine is typically mild.
Not supported by the provided label excerpts.
Sweating in patients taking venlafaxine lasts from a few minutes to several hours.
Not supported by the provided label excerpts.
Abdominal pain occurs in 5% to 10% of patients taking venlafaxine.
Not supported by the provided label excerpts.
Abdominal pain in patients taking venlafaxine is typically mild to moderate.
Not supported by the provided label excerpts.
Abdominal pain in patients taking venlafaxine lasts from a few days to several weeks.
Not supported by the provided label excerpts.
Constipation occurs in 5% to 10% of patients taking venlafaxine.
Not supported by the provided label excerpts.
Constipation in patients taking venlafaxine is typically mild.
Not supported by the provided label excerpts.
Constipation in patients taking venlafaxine lasts from a few days to several weeks.
Not supported by the provided label excerpts.
Diarrhea occurs in 5% to 10% of patients taking venlafaxine.
Not supported by the provided label excerpts.
Diarrhea in patients taking venlafaxine is typically mild.
Not supported by the provided label excerpts.
Diarrhea in patients taking venlafaxine lasts from a few days to several weeks.
Not supported by the provided label excerpts.
Serotonin syndrome is a serious side effect of venlafaxine that is rare but potentially life-threatening.
Not supported by the provided label excerpts.
Symptoms of serotonin syndrome associated with venlafaxine include agitation, confusion, fever, sweating, and tremors.
Not supported by the provided label excerpts.
Suicidal thoughts or behaviors are a serious side effect of venlafaxine that is rare but potentially life-threatening.
The provided excerpts establish increased risk of suicidality and monitoring requirements, but do not support “rare” or “potentially life-threatening” phrasing.
Symptoms of suicidal thoughts or behaviors associated with venlafaxine include suicidal thoughts, behaviors, or attempts.
Partially supported conceptually by “suicidality”/“suicidal thoughts and behavior,” but the provided excerpts do not support “attempts” specifically or the full symptom mapping as written.
Seizures are a serious side effect of venlafaxine that is rare but potentially life-threatening.
Not supported by the provided label excerpts.
Symptoms of seizures associated with venlafaxine include seizures or convulsions.
Not supported by the provided label excerpts.
Venlafaxine typically starts working within 1 to 2 weeks of treatment.
Not supported by the provided label excerpts.
Venlafaxine may take up to 6 weeks to reach full effect.
Not supported by the provided label excerpts.
Stopping venlafaxine suddenly can lead to withdrawal symptoms.
Not supported by the provided label excerpts.
Contradictions
Important Omissions
Boxed Warning/Section 5.1 monitoring requirements and scope: the need to monitor patients closely for clinical worsening and emergence of suicidality, especially early in treatment and at dose changes, including daily observation by families/caregivers, is not mentioned.
Importance:
High
Pediatric limitation: venlafaxine hydrochloride extended-release capsules are not approved for pediatric use.
Importance:
High
Safety Assessment
Potential Patient Risk:
High
Most claims (indication, mechanism, adverse reaction frequencies/severity/duration, serotonin syndrome/seizures, onset of effect, and withdrawal timing) are not supported by the provided label excerpts. Additionally, key boxed-warning monitoring and pediatric-use limitation content is omitted.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
The AI response makes many claims (indications, mechanism, adverse reactions with specific frequencies/durations, rare serious risks, onset/withdrawal timing) that are not supported by the supplied FDA label excerpts. It also omits key boxed-warning monitoring and pediatric non-approval statements present in the provided label text.
Suggested Improvement
Restrict claims to the provided label excerpts (Boxed Warning, Section 5.1, Section 8.4, Section 17) or supply additional label sections (Indications, Warnings/Precautions, Adverse Reactions, Clinical Pharmacology) before asserting specific percentages, timelines, mechanism language, or withdrawal/onset statements.